💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zolpidem

CHEMBL911 Phase 4 अनुमोदित Small molecule
Half-Life
2.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
307.4 g/mol
LogP
2.5
Phase
4

This sedative-hypnotic medication is widely prescribed for short-term treatment of insomnia, helping people fall asleep more quickly and stay asleep longer. It works by binding to GABA receptors in the brain in a targeted way to produce sedation without the same degree of anxiety relief as benzodiazepines. Complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating have been reported, and women typically require a lower dose due to slower drug clearance.

आणविक भार

307.3950 g/mol

LogP

2.50

TPSA

37.60 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अनिद्रा अल्ज़ाइमर रोग अस्थमा उच्च रक्तचाप क्रॉनिक किडनी डिज़ीज़ जनरलाइज़्ड एंग्ज़ाइटी डिसऑर्डर दर्द प्रबंधन दीर्घकालिक दर्द पार्किंसन रोग बाइपोलर डिसऑर्डर माइग्रेन मिर्गी (एपिलेप्सी) मोटापा सिज़ोफ्रेनिया स्तन कैंसर हृदय विफलता

दवा वर्ग

N — N - तंत्रिका तंत्र

क्रिया का तंत्र

Selective GABA-A receptor alpha-1 subunit agonist.

Pharmacokinetics (PK)

Half-Life 2.5 hours

Pharmacodynamics (PD)

तंत्र

Selective GABA-A receptor alpha-1 subunit agonist.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H21N3O

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
घूर्णनीय बंधन

                        
3

                    

                    
                    
                    

                        
भारी परमाणु

                        
23

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            GABRA1 (GABA-A रिसेप्टर)
                            Agonist
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            CYP3A4 (साइटोक्रोम P450 3A4 (CYP3A4))
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Zolpidem + Alprazolam
                            
                        

                        
                        
Combining alprazolam with zolpidem produces additive CNS depression, profound sedation, psychomotor impairment, and respiratory depression risk.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Zolpidem + Diazepam
                            
                        

                        
                        
Diazepam and zolpidem together produce compounded GABA-A-mediated CNS depression, with risk of severe sedation and respiratory compromise.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Zolpidem + Warfarin
                            
                        

                        
                        
Zolpidem has been reported to modestly increase warfarin anticoagulation in isolated case reports; routine clinical concern is low.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Zolpidem + Gabapentin
                            
                        

                        
                        
Gabapentin adds to zolpidem's CNS depressant effects, increasing the risk of excessive sedation, falls, and next-morning psychomotor impairment.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
This sedative-hypnotic medication is widely prescribed for short-term treatment of insomnia, helping people fall asleep more quickly and stay asleep longer. It works by binding to GABA receptors in the brain in a targeted way to produce sedation without the same degree of anxiety relief as benzodiazepines. Complex sleep behaviors including sleepwalking, sleep-driving, and sleep-eating have been reported, and women typically require a lower dose due to slower drug clearance.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Selective GABA-A receptor alpha-1 subunit agonist.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Zolpidem: Half-life: 2.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Zolpidem is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL911.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5732.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.